Form 4: Biote Corp Director Receives Equity Compensation

Director Stephen Mark Cone was granted 31,481 deferred settlement RSUs and 130,000 stock options by Biote Corp.

Summary

• Director Stephen Mark Cone received an equity grant on May 12, 2026.
• The grant includes 31,481 Deferred Settlement RSUs, which are fully vested but deferred until separation from service.
• The grant also includes 130,000 stock options with an exercise price of $2.20 per share.
• The stock options are scheduled to vest on May 12, 2027, or the day prior to the 2027 Annual Meeting, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial trajectory.

Positives

• Equity-based compensation aligns the interests of the director with those of shareholders.
• The RSU grant is fully vested, indicating immediate commitment to the company's long-term performance.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Potential dilution of share value upon the exercise of the 130,000 stock options.
• Market volatility affecting the value of the underlying Class A Common Stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the healthcare and biotechnology sectors.

Comparison to Industry Standards

• The use of deferred settlement RSUs and time-vested options is consistent with standard executive and director compensation packages in the mid-cap biotech industry.
• The vesting schedule of one year for options is relatively standard for director compensation.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new stock options.

Next Steps

• Vesting of stock options on May 12, 2027.

Key Dates

Keywords

Biote Corp, BTMD, Form 4, Director Compensation, Equity Grant, Stock Options, RSU